Abstract: SA-PO0801
Treatment Trends in European Patients with Primary Membranous Nephropathy (PMN): Insights from the European Rare Kidney Disease Registry (ERKReg)
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Hofstetter, Jonas, Heidelberg University Hospital, Heidelberg, Germany
- van de Logt, Anne-Els, Radboud University Medical Centre, Nijmegen, Netherlands
- Roccatello, Dario, University of Torino-Ospedale HUB Torino Nord, Turin, Italy
- Morales, Enrique, Madrid Hospital Universitario 12 de Octubre, Madrid, Spain
- Kapsia, Eleni, Athens Laiko General Hospital of Athens, Athens, Greece
- Claes, Kathleen, Leuven University Hospitals, Leuven, Belgium
- Servais, Aude, Necker-Enfants Malades University Hospital, Paris, France
- Alberici, Federico, Brescia ASST Spedali Civili Brescia, Brescia, Italy
- Goedecke, Vega, Hannover Medical School, Hannover, Germany
- Moeller, Marcus J., Aachen University Hospital, Aachen, Germany
- Diaz Encarnacion, Montserrat M., Barcelona Hospital de la Santa Creu I Sant Pau and Fundacio Puigvert/IUNA, Barcelona, Spain
- Gesualdo, Loreto, Bari AOU Consorziale policlinico di Bari-Ospedale Pediatrico Giovanni XXIII, Bari, Italy
- Yau, Vincent M, F Hoffmann-La Roche AG, Basel, Switzerland
- Boston, Heather, F Hoffmann-La Roche AG, Basel, Switzerland
- Schindler, Thomas, F Hoffmann-La Roche AG, Basel, Switzerland
- Schaefer, Franz, Heidelberg University Hospital, Heidelberg, Germany
Background
pMN is the most common cause of nephrotic syndrome and one-third of untreated individuals experience spontaneous remission. For medium- to high-risk patients, the 2012 KDIGO glomerulopathy guideline recommended treatment with alternating cycles of corticosteroids and alkylating agents or calcineurin inhibitors (CNIs). The 2021 KDIGO guideline update introduced Rituximab as an alternative treatment option. We sought to understand how treatment patterns in pMN patients have changed in Europe in response to the 2021 KDIGO guideline.
Methods
Information on immunosuppressive medications applied since 01/2018 was available for 274 pMN patients from 10 countries in ERKReg and was analyzed for equal time periods preceding and following the publication of the 2021 KDIGO guideline update.
Results
Immunosuppressive therapies during the total 7-year observation period included CNI (66 pts), CD20 antibodies (116 pts), intravenous and oral steroids (82 pts), cyclophosphamide (20 pts), and MMF (16 pts). 115 pts (42%) did not receive any immunosuppressive therapy.
Following the KDIGO Guideline update in 10/2021, the proportion of patients managed without any immunosuppressive treatment markedly increased. Among the patients treated, CD20 antibody use increased whereas the use of cyclophosphamide markedly decreased. CNI continued to be prescribed in 30% of patients.
Conclusion
Immunosuppressive prescription patterns in pMN patients followed in ERKReg have slightly changed in Europe during the past 7 years, with a higher proportion managed without immunosuppressive therapy and an increasing use of CD20 antibodies among those treated.
Immunosuppressants applied prior to and after publication of 2021 KDIGO Guideline.